Axogen Inc vs Jabil Inc — how do they compare? Axogen Inc trades at $38.65 (market cap $2.06B), while Jabil Inc trades at $327.45 (market cap $34.25B). The key difference: Jabil Inc is far larger — about 16.6× Axogen Inc's market cap, and Jabil Inc pays a 0.1% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | JBL | |
|---|---|---|
Market Cap | $2.06B | $34.25B |
Sector | Technology | Technology |
52-Week High | $46.19 | $385.50 |
52-Week Low | $11.28 | $192.49 |
Enterprise Value | $1.98B | $36.78B |
Dividend Yield | — | 0.1% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
JBL trades at $321.96, down 2.52% today, with a bearish technical signal but strong fundamental momentum. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.16 exceeding the $3.10 estimate. Revenue growth is robust, projected to rise from $29.80B in 2025 to $33.60B in 2026, driven by AI infrastructure demand. The stock faces near-term pressure but maintains a 50% buy rating from analysts, with a consensus price target of $436.50 suggesting significant upside potential from current levels.
JBL's outlook is supported by AI-driven expansion and solid earnings, but high valuation multiples like a P/E of 40.9 pose risks if growth slows. Competitive pressures in electronics manufacturing and macroeconomic volatility could impact margins. Investors should weigh the strong analyst consensus against technical bearish signals and elevated valuation before committing capital.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →